Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.62 |
| ▸ | CDK9 | P50750 | 1/20 | 0.62 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.51 |
| ▸ | NFATC1 | O95644 | 6/20 | 0.51 |
| ▸ | GSK3B | P49841 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268299 | 1.00 | CCNT1 (0.62) | CCNT1CDK9HASPINCYP2A6IMPDH2 | |
| Hydrochloric Acid SCHEMBL3831446 | 0.98 | CCNT1 (0.60) | CCNT1CDK9HASPINCYP2A6IMPDH2 | |
| SCHEMBL2263957 | 0.85 | CCNT1 (0.62) | CCNT1CDK9HASPINCYP2A6IMPDH2 | |
| SCHEMBL27773730 | 0.81 | DYRK1A (0.51) | CCNT1CDK9HASPINDYRK1ANFATC1 | |
| SCHEMBL4268145 | 0.77 | CCNT1 (0.65) | CCNT1CDK9HASPINDYRK1ANFATC1 | |
| SCHEMBL4268142 | 0.77 | CCNT1 (0.65) | CCNT1CDK9HASPINDYRK1ANFATC1 | |
| SCHEMBL3594684 | 0.76 | CCNT1 (0.56) | CCNT1CDK9HASPINCYP2A6IMPDH2 | |
| SCHEMBL26700908 | 0.75 | CCNT1 (0.58) | CCNT1CDK9HASPINCYP2A6IMPDH2 | |
| 3-Formylindole SCHEMBL29082887 | 0.74 | CYP2A6 (0.77) | CCNT1CDK9HASPINCYP2A6IMPDH2 | |
| SCHEMBL23600353 | 0.74 | CGAS (0.51) | CCNT1CDK9HASPINDYRK1ANFATC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719396-A2 | NON-PEPTIDE SMALL MOLECULE FGF14:NAV1.6 CHANNEL COMPLEX PROTEIN-PROTEIN INTERACTION MODULATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12559487-B2 | Crosslinked optically active secondary amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-24 | — | — | US | disclosed |
| EP-4688776-A1 | 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN | Acerta Pharma B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024254218-A2 | NON-PEPTIDE SMALL MOLECULE FGF14:NAV1.6 CHANNEL COMPLEX PROTEIN-PROTEIN INTERACTION MODULATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024201240-A1 | 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN | ACERTA PHARMA B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| CN-118139864-A | New compounds | 西特瑞治疗有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-110526854-B | Alpha, beta-unsaturated ketone derivative, preparation method and application thereof as medicine | 宁夏医科大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20220380365-A1 | CROSSLINKED OPTICALLY ACTIVE SECONDARY AMINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-12-01 | — | — | US | disclosed |
| EP-4003997-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380365-A1 | CROSSLINKED OPTICALLY ACTIVE SECONDARY AMINE DERIVATIVE | MLLT3, MLLT1, MEN1 | CCNT1 1288/4885CDK9 307/4885HASPIN 1466/4885 |
| US-12559487-B2 | Crosslinked optically active secondary amine derivative | MLLT3, MLLT1, FLI1 | CCNT1 1200/4885CDK9 489/4885HASPIN 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.